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In this review we present an overview of recent developments in the management of hereditary ovarian
cancer. Until recently, intensive screening of the ovaries was recommended to mutation carriers and
their ﬁrst-degree female relatives. However, since screening is not effective in detecting early-stage
ovarian cancer, women are counselled for a prophylactic bilateral salpingo-oophorectomy (pBSO) shortly
after child-bearing age (>35 years). Many mutation carriers already choose to undergo pBSO to reduce






important (psychosexual) issues in life. Due to the protective effect of oral contraceptives regarding
ovarian cancer, we advise women at increased risk of ovarian cancer to use oral contraceptive pills for
3–5 years early in life (<25 years of age), when the absolute incidence of breast cancer is extremely
low. A transient increased relative risk of breast cancer due to oral contraceptives at this age will result
in a negligible increased absolute number of breast cancers, while the risk reduction of ovarian cancer
remains for life. Research should aim at ﬁnding new molecular markers and screening strategies for
detecting early-stage ovarian cancer in women with a hereditary ovarian cancer trait.
© 2009 Elsevier Ireland Ltd. All rights reserved.
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. Introduction
At least 10% of ovarian carcinomas are associated with a highly
enetrant, autosomal, dominant genetic predisposition [1]. Three
linicalmanifestationsofhereditaryovariancancerhavebeen iden-
iﬁed: site-speciﬁcovarian cancer; hereditarybreast and/orovarian
ancer (HBOC)mostly due toBRCA1 andBRCA2genemutations; and
ynch syndrome, formerly known as hereditary non-polyposis col-
rectal cancer (HNPCC) syndrome [2]. BRCA germ-line mutations
ccount for more than 90% of all hereditary ovarian carcinomas,
hereas most of the remaining 10% are caused by mutations in
ismatch repair genes, MLH1, MSH2, MSH6, PMS2, which are sus-
eptibility genes for Lynch syndrome [3,4].
An accurate estimation of the risk of ovarian cancer is crucial
n counselling these women, since important decisions have to be
ade during an often crucial phase of life, the child-bearing years.
isk assessment and counselling arebasedonpenetrance estimates
f ovarian cancer at certain ages, which have been investigated by
any studies worldwide. Unfortunately, those penetrance studies
how varying results, due to the choice of the population studied
nd hence the cancer incidence. Estimates of the average pene-
rance up to 70 years of age are 40% (95% CI, 35–46%) for BRCA1
nd 18% (95% CI, 13–23%) for BRCA2 mutation carriers [5]. In BRCA
arriers, there is no inﬂuence of birth cohort on the risk of ovarian
ancer. Estimates of ovarian cancer penetrance in Lynch syndrome
epend on the type of the mutation and vary between 3% and 14%,
ompared with a 1.4% risk in the general population. In a retro-
pective cohort study, Watson and Lynch found a lifetime risk of
varian cancer of 4–6% for MLH1 and 8–12% for MSH2 mutation
arriers, with a signiﬁcant risk difference associated with year of
irth [6]: women born after 1946 carried twice the risk of ovar-
an cancer as women born before 1946. The highest risk period for
varian cancer in MLH1 and MSH2 carriers was between 40 and 55
ears of age [6].
In this overview we ﬁrst present a ﬁctitious case scenario of a
atient with a germ-line mutation in a BRCA1 gene and the clinical
ilemmas she encounters. We then review the clinical considera-
ions and related current management strategies and argue which
s the preferred strategy. For more clinical considerations and cur-
entmanagement strategies related to the decision to go for genetic
esting and the reduction of breast and ovarian cancer risk, we refer
eaders to the recently published guideline of the American College
f Obstetricians and Gynecologists (ACOG) [7].
. Our patient and her clinical dilemmas
Our case scenario concerns a woman aged 32 years. She has one
on (aged 4 years). She has a family history of breast and ovarian
ancer. Her mother was diagnosed with ovarian cancer at the age
f 60 and died at the age of 61. Her sister (aged 37) was diagnosed
ith breast cancer at the age of 33 and was offered genetic testing.
he appears to be a BRCA1mutation carrier. No other cases of breast
r ovarian cancer were reported in this (small) family.
There are several clinical dilemmas our patient wants to discuss
ith her doctor:
Should I go for genetic testing and what are the consequences?
How can I reduce the risk of breast cancer?What are the pros and
cons of prophylactic surgery and breast cancer screening?
How can I reduce the risk of ovarian cancer? What are the pros
and cons of prophylactic bilateral salpingo-oophorectomy and
ovarian cancer screening?
Is it safe to have another child? What are the risks for my new
baby and are there possibilities to reduce this risk?ritas 64 (2009) 172–176 173
Our patient decides to undergo genetic testing. If she proves
to be a carrier, given the early age of onset of breast cancer in her
sister, shewants tohaveaprophylacticmastectomy. Shehasnotyet
decided on whether to have another pregnancy or ovarian cancer
risk reduction.
Genetic testing is performed and it appears that our patient also
carries the BRCA1mutation. She decides to have a bilateral prophy-
lactic mastectomy and reconstructive surgery. After that she visits
the family cancer clinic to discuss how tomanage her increased risk
of ovarian cancer and her desire to have another child.
3. How to reduce the risk of (advanced) ovarian cancer
Women diagnosed with a BRCA1/2 mutation are given several
options to reduce their risk of dying of ovarian cancer. One is
to choose screening, with the main objective of identifying ovar-
ian cancer in an early-stage, to improve the prognosis and reduce
morbidity and mortality. Available screening tests for ovarian can-
cer include bimanual pelvic examination, transvaginal ultrasound
(TVU) and measurements of serum CA125.
3.1. Transvaginal ultrasound (TVU)
There are several criteria for the deﬁnition of an abnormal TVU
to predict ovarian malignancy [8]. According to the Sassone crite-
ria, in premenopausal women only simple cysts of more than 6 cm
need further investigation [9]. Themain limitation to theuse of TVU
as a screening tool is the high false-positive rate, especially in pre-
menopausal women [10]. Due to frequent follicle cyst formation
and persistent follicles in premenopausal ovaries, criteria for fur-
ther investigation need to be described carefully and have a large
effect on numbers needed to operate to ﬁnd one ovarian cancer
[11,12].
In postmenopausal women, the speciﬁcity of TVU is higher than
in premenopausal women, due to the absence of follicle cyst for-
mation [13,14]. However, even in postmenopausal women adnexal
lesions are frequently found [15]. Altered blood vessel resistance in
malignant compared to benign ovarian cysts visualized by Doppler
imaging was hoped to improve the identiﬁcation of malignant
ovarian tumors in high-risk populations [16]. However, due to con-
siderable overlap in the measurements of benign and malignant
tumors, its role in ovarian cancer screening has not been ﬁrmly
established [17].
3.2. Serum marker CA125 and other markers
CA125 is expressed by coelomic andMullerian epithelia, but the
surface epithelium of normal ovaries does not express CA125 [18].
The ﬁnding that CA125 is a serum marker for ovarian cancer gave
the promise of a biomarker for the monitoring of (early) ovarian
cancer [19]. However, as ovarian cancer presents late and spreads
early, the sensitivity of serumCA125 is very low for the early detec-
tion of ovarian cancer, since only 25–50%of thewomenwith a stage
I ovarian tumor have an elevated serum CA125 level at the time of
diagnosis [20]. In addition, especially in premenopausal women,
an elevated CA125 level is not very speciﬁc for the diagnosis of
ovarian cancer, as it can also be found in benign and physiologi-
cal conditions, including menstruation, pregnancy, endometriosis,
uterine leiomyomas, infectious disease, as well as in other malig-
nancies [21,22]. The application of algorithms for calculating the
risk of ovarian cancer algorithm inhealthypostmenopausalwomen
[23,24] as well as in women at increased risk [25,26] may be useful
in aiding the interpretation of CA125 and ultrasound results. How-
ever, the end-point of these studies should not be the detection
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ortality from ovarian cancer from the UKCTOCS study will not be
vailable before 2014.
It is therefore of the utmost importance to develop new circu-
ating (panels of) biomarkers which are speciﬁc for (early) ovarian
ancer and speciﬁcally in mutation carriers, to improve traditional
creening results. More than 30 serum markers have been eval-
ated alone and in combination with CA125, and mathematical
echniques are being developed to analyze combinations ofmarker
evels to improve sensitivity and speciﬁcity. Recent candidates
nclude: HE4, mesothelin, M-CSF, osteopontin, kallikrein(s), and
olubleEGF receptor [22] and thecombineduseofmultiplemarkers
hrough an artiﬁcial neural network [27]. Others have started clini-
al trials to assess the sensitivity and speciﬁcity of serumproteomic
atterns to identify early ovarian cancer [28].
The initial resultshavecauseda lotof interestbut alsomuchcon-
roversy regarding the reproducibility, sensitivity, and speciﬁcity
f this new technology utilizing surface-enhanced laser desorption
nd ionization mass spectrometry (SELDI-MS) in ovarian cancer.
dditional researchneeds tobedone toﬁndprotein signallingpath-
ays in humans,which could lead to the identiﬁcation ofmolecular
arkers of early-stage ovarian cancer [29]. Although there is opti-
ism that further developments in serum proteomic analysis will
rovide powerful methods for screening in ovarian cancer, current
linical screening practice will have to do without proteomics, and
nly prospective studies in the future will tell whether proteomics
ill be able to detect ovarian cancer at an early, preclinical stage
30].
.3. Combining these screening tests into screening strategies
In 12 cohort studies, four prospective and eight retrospec-
ive, the effectiveness of conventional ovarian cancer screening
n women with a BRCA1/2 mutation and in women at high risk
f hereditary breast and ovarian cancer has been determined
11,31–41]. The total sample in these studies is 5298women,with a
otal of 13,979 screening contacts. Only 1435 (27.1%) women were
roven BRCA1/2 mutation carriers. The results of the screening of
he subset of proven BRCA1/2 mutation carriers in the 12 studies
ere as follows. A total of 43 screen-detected ovarian cancers and
interval cancers were found. Of the 43 screen-detected cancers,
6 cancers were found in an early-stage (FIGO stage I/II), and six
f these women had been treated for breast cancer. Of these six
omen, it is not certain whether the tumor was a primary ovarian
ancer or an ovarian metastasis from the breast cancer. The inter-
al cancers were mostly in an advanced stage (FIGO stage II–IV).
he conclusion is that annual screening, by transvaginal ultrasound
nd serum CA125 in women with a hereditary ovarian cancer trait,
s ineffective in detecting tumors at a sufﬁciently early-stage to
mprove survival [42].
.4. Early signs and symptoms?
Ovarian cancer has no premalignant signs or symptoms, other
han non-speciﬁc complaints. For that reason, ovarian cancer
s called a ‘silent killer’. However, in 2007, the Gynaecologic
ancer Foundation, Society of Gynaecologic Oncologists and
merican Cancer Society originated an Ovarian Cancer Symptoms
onsensus Statement regarding the symptoms of ovarian cancer
http://www.sgo.org/publications/OvarianCancerSymptoms.pdf).
he symptoms that are described in this Consensus Statement are
ore likely to occur in women with ovarian cancer than in the
eneral population. These symptoms include: bloating, pelvic or
bdominal pain, pain in the back or legs, diarrhea, gas, nausea,
onstipation, indigestion, difﬁculty eating or feeling full quickly,
rinary symptoms, pain during sex, abnormal vaginal bleeding
nd trouble breathing. As early diagnosis is associated with anritas 64 (2009) 172–176
improved prognosis, women are advised to see their doctor once
they have symptoms almost daily for more than a few weeks.
However, these symptoms are not as speciﬁc as we would like
them to be, and knowledge of the biology of ovarian cancer (being
a surface tumor with early shedding) does not make it plausible
for these signs to lead to early diagnosis and improved survival. On
the other hand, they may cause an enormous amount of worry and
costs, as these signs are non-speciﬁc and are frequently reported
by women in the general population [43,44].
3.5. Alternative screening strategies
As the currently available screening methods, including CA125
and TVU, lack the necessary sensitivity and speciﬁcity to provide
accurate and cost-efﬁcient early-stage cancer screening for the
high-risk population, other ways of screening need to be assessed.
As none of the currently available screening modalities is effec-
tive in ﬁnding early-stage ovarian cancer and as the prognosis of
advanced ovarian cancer is poor, it is time to stop ovarian can-
cer screening with the conventional tools [31]. Instead, alternative
strategies need to be explored with the use of new molecular
(serum) markers to detect ovarian cancer in an initial phase. In
the UK, a more frequent multi-modality CA125 screening algo-
rithmhas beenproposedby Jacobs et al. in healthypostmenopausal
women, in which not only the absolute value but the relative
value (increment) of serial CA125 values is taken into account
[23,45]. Whether this algorithm is also applicable to pre- and post-
menopausal women at high risk is as yet unknown.
3.6. Prophylactic bilateral salpingo-oophorectomy
As effective screening tools for detecting premalignant ovarian
lesions or early-stage ovarian cancer are not yet available, and as
there is currently no evidence of amortality reduction fromovarian
cancer screening, the only effective option at present for women
with a hereditary susceptibility to ovarian cancer is prophylactic
bilateral salpingo-oophorectomy (pBSO) [46]. In a meta-analysis
of 10 studies that investigated breast or gynecologic cancer out-
comes in BRCA1/2 mutation carriers who had undergone pBSO, it
was found that pBSO was associated with a statistically signiﬁcant
reduction in the riskofBRCA1/2-associatedovarianor fallopian tube
cancer (HR=0.21; 95%CI =0.12–0.39) [46].Datawere insufﬁcient to
obtain separate estimates for ovarian and fallopian tube cancer risk
reduction with pBSO in BRCA1 or BRCA2 mutation carriers. In addi-
tion, there is an ongoing prospective, international, two-cohort,
non-randomized study of women at genetic risk of ovarian cancer,
who chose to undergo either pBSO or screening at study enroll-
ment, with the main aim of quantifying the incidence of ovarian
and breast cancer in the two study groups [24]. Study accrual was
completed in 2006, and we are waiting for the follow-up data.
The majority of women who have a proven BRCA1/2 mutation
are now counselled to undergo pBSO after child-bearing age [47].
In addition, pBSO before menopause has a protective effect on
the incidence of breast cancer [48]. As the risk of ovarian cancer
begins to rise in the late 30s and early 40s for BRCA1 carriers and
approximately10years later forwomenwithaBRCA2mutation, the
advised age for pBSO in BRCA1 carriers is 35–40 years and in BRCA2
carriers 40–45 years. For women who still want to opt for screen-
ing or have reasons to preserve fertility, no effective prophylactic
strategy exists.
Ovarian cancers in women with Lynch syndrome are often
non-serous [49]. Therefore the effectiveness of ovarian cancer
surveillance in Lynch syndrome might differ from that in BRCA1/2
mutation carriers. In a meta-analysis, ovarian tumors with mis-
match repair deﬁciency had an earlier stage disease at presentation
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roven to be better [50]. For women with Lynch syndrome, annual
creening from age 30 years followed by prophylactic surgery (hys-
erectomy and pBSO) from age 40 years, or 5 years before the age
f the youngest affected family member, seems to be the most
ffective gynecologic cancer prevention strategy. However, the
ncremental beneﬁtoverprophylactic surgeryalonewasattainedat
ubstantial costs [49]. Hormone replacement therapy until the age
f 50 years is indicated for women with Lynch syndrome who have
o deal with early surgical menopause. After pBSO in BRCA1/2 car-
iers, breast cancer screening should continue, as well as colorectal
ancer screening in women with Lynch syndrome after gynecolog-
cal prophylactic surgery.
.7. Procedure of gynecological prophylactic surgery
In BRCA1/2mutation carriers, the minimum prophylactic proce-
ure is a bilateral salpingo-oophorectomy. The procedure should
tart with peritoneal lavage and cytological examination to detect
ccult ovarian, peritoneal or tubal cancers, which are reported to
e present in about 3% of BRCA1/2 carriers who undergo pBSO. It is
mportant that the ovaries and tubes are handled with care not to
pread occult cancer through the abdominal cavity. For the same
eason, tissue should be removed using an endo-pouch. During
he histopathological examination, it is important that the entire
varies and fallopian tubes are serially sectioned so that small and
icroscopic lesions are not missed. Whether hysterectomy should
e part of the prophylactic surgery in BRCA1/2 mutation carriers
s debatable, because there is no evidence that a hysterectomy
dds to reducing the risk of fallopian tube cancer more than a
omplete BSO alone [50]. For that reason, we recommend a pBSO
ithout hysterectomy. In women with Lynch syndrome, however,
isk-reducing surgery should consist of pBSO together with a total
ysterectomy.
. Reproductive issues
.1. Oral contraceptive pills
In general, current users of oral contraceptives have a small
ncreased relative risk of breast cancer (odds ratio: 1.24; 95% CI:
.15–1.33) [51]. This increased risk disappears after cessationof use
51]. The use of oral contraceptive pills is controversial in women
ith an increased risk of breast cancer. There is an increased risk of
reast cancer forBRCA1/2mutation carrierswhoeverusedoral con-
raceptives (adjusted hazard ratio: 1.47; 95% CI, 1.16–1.87) [52]. No
vidence was found among BRCA1/2 mutation carriers that current
se of oral contraceptives is associated with risk of breast cancer
ore strongly than is past use, as is found in the general popula-
ion [52].However, theuseof oral contraceptives confers long-term
rotection against ovarian cancer; the use of oral contraceptive
gents for as long as 5 years decreases the risk of ovarian cancer in
ater life by about 50% [53]. Use during the 1960s, 1970s, and 1980s
as associated with similar proportional risk reductions, although
ypical estrogen doses in the 1960s were more than double those
n the 1980s. The incidence of mucinous tumors (12% of the total)
eemed little affected by oral contraceptives, but otherwise the
roportional risk reduction did not vary much between different
istological types [54]. Where the same effect was found for BRCA1
utation carriers, the number of ovarian cancer cases in BRCA2
utation carriers was too small to draw deﬁnitive conclusions..2. Worries about transmitting the mutation to children
Women carrying a BRCA1/2 or Lynch syndrome gene mutation
ave a 50% chance of conceiving a baby with the same mutation.
here are a few options available to avoid having a child with theritas 64 (2009) 172–176 175
same mutation and the availability of these options differs across
countries. Besides avoiding child-bearing, options are pregnancy
surrogate, and DNA analysis of tissue obtained in early pregnancy
by chorionic villous biopsy or amniotic ﬂuid assessment, with an
abortion if the fetus is affected. Another option is to perform in vitro
fertilization with pre-implantation genetic diagnosis (PGD) of the
retrieved embryos, followed by selection of embryo(s) without a
mutation and transfer of a selected embryo to the uterus [55].
5. Our patient
At the age of 34, our patient decides to become pregnant again.
Before that she asked for information about PGD, to avoid the birth
of an affected child. However, the demands of the procedure per-
suaded the couple to decline this option. She became pregnant and
delivered a healthy baby girl.
Four years later, at the age of 38 years, she decides to undergo
a pBSO. She is counselled about the quality of life effects of early
surgical menopause and is offered hormone replacement therapy
[56,57].
Her sister had decided to have a pBSO as well, but was advised
not to take hormone replacement therapy because of an increased
risk of breast cancer recurrence [58–60]. Hot ﬂushes occurred and
were treated with venlafaxine [61].
6. Conclusions
Until recently, intensive screening of the ovaries was recom-
mended tomutation carriers and theirﬁrst-degree female relatives.
However, since conventional screening is not effective in detect-
ing early-stage ovarian cancer and new strategies are not yet
available, women should be counselled regarding a prophylactic
salpingo-oophorectomy after child-bearing age (>35 years). The
favourable effects in terms of a reduced risk of ovarian cancer need
to be weighed against the physical and psychosexual side-effects
of early surgical menopause. Counselling will help women to make
informed decisions about the optimal preventive health strategy.
Research should aim at ﬁnding newmolecularmarkers and screen-
ing strategies for detecting early-stage ovarian cancer in women
with a hereditary ovarian cancer trait.
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